Legal & General Group Plc raised its stake in shares of Blueprint Medicines Corporation (NASDAQ:BPMC) by 31.8% during the first quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 5,884 shares of the biotechnology company’s stock after buying an additional 1,419 shares during the period. Legal & General Group Plc’s holdings in Blueprint Medicines Corporation were worth $235,000 at the end of the most recent quarter.

Several other institutional investors have also modified their holdings of BPMC. Swiss National Bank raised its position in shares of Blueprint Medicines Corporation by 12.1% in the first quarter. Swiss National Bank now owns 46,300 shares of the biotechnology company’s stock valued at $1,852,000 after buying an additional 5,000 shares during the last quarter. Bank of New York Mellon Corp raised its position in shares of Blueprint Medicines Corporation by 29.0% in the first quarter. Bank of New York Mellon Corp now owns 120,568 shares of the biotechnology company’s stock valued at $4,822,000 after buying an additional 27,095 shares during the last quarter. Henderson Group PLC acquired a new position in shares of Blueprint Medicines Corporation during the first quarter valued at about $1,200,000. Jennison Associates LLC acquired a new position in shares of Blueprint Medicines Corporation during the first quarter valued at about $5,998,000. Finally, Wells Fargo & Company MN raised its position in shares of Blueprint Medicines Corporation by 40.2% in the first quarter. Wells Fargo & Company MN now owns 21,928 shares of the biotechnology company’s stock valued at $877,000 after buying an additional 6,286 shares during the last quarter. Institutional investors own 88.67% of the company’s stock.

Blueprint Medicines Corporation (NASDAQ BPMC) traded up 0.04% during midday trading on Friday, hitting $46.98. The company had a trading volume of 72,569 shares. Blueprint Medicines Corporation has a 52 week low of $23.71 and a 52 week high of $56.81. The firm’s 50 day moving average is $51.95 and its 200-day moving average is $42.50. The firm’s market capitalization is $1.84 billion.

Blueprint Medicines Corporation (NASDAQ:BPMC) last released its earnings results on Wednesday, August 2nd. The biotechnology company reported ($0.86) EPS for the quarter, missing the Zacks’ consensus estimate of ($0.75) by $0.11. The firm had revenue of $5.89 million during the quarter, compared to the consensus estimate of $5.96 million. Blueprint Medicines Corporation had a negative net margin of 388.91% and a negative return on equity of 45.58%. The firm’s revenue was down 16.7% compared to the same quarter last year. During the same period in the prior year, the company earned ($0.70) EPS. On average, equities research analysts expect that Blueprint Medicines Corporation will post ($3.59) EPS for the current fiscal year.

ILLEGAL ACTIVITY WARNING: “Blueprint Medicines Corporation (NASDAQ:BPMC) Position Boosted by Legal & General Group Plc” was reported by Watch List News and is owned by of Watch List News. If you are viewing this report on another domain, it was illegally stolen and republished in violation of US & international trademark & copyright laws. The legal version of this report can be accessed at https://www.watchlistnews.com/blueprint-medicines-corporation-nasdaqbpmc-position-boosted-by-legal-general-group-plc/1475100.html.

Several equities analysts have recently issued reports on the company. Zacks Investment Research upgraded Blueprint Medicines Corporation from a “sell” rating to a “hold” rating in a research note on Monday, July 17th. BidaskClub raised Blueprint Medicines Corporation from a “buy” rating to a “strong-buy” rating in a report on Tuesday, June 27th. Canaccord Genuity set a $56.00 price objective on Blueprint Medicines Corporation and gave the company a “buy” rating in a report on Wednesday, August 2nd. Jefferies Group LLC raised their price objective on Blueprint Medicines Corporation from $42.00 to $52.00 and gave the company a “buy” rating in a report on Thursday, May 4th. Finally, TheStreet downgraded Blueprint Medicines Corporation from a “c-” rating to a “d+” rating in a report on Wednesday, May 3rd. One investment analyst has rated the stock with a sell rating, seven have given a buy rating and one has assigned a strong buy rating to the company’s stock. The stock currently has an average rating of “Buy” and an average price target of $47.90.

In other Blueprint Medicines Corporation news, insider Kate Haviland sold 7,265 shares of the company’s stock in a transaction dated Wednesday, July 5th. The shares were sold at an average price of $54.66, for a total transaction of $397,104.90. Following the completion of the sale, the insider now directly owns 7,265 shares in the company, valued at $397,104.90. The transaction was disclosed in a document filed with the SEC, which is accessible through this link. Also, Director Daniel Lynch sold 7,500 shares of the company’s stock in a transaction dated Wednesday, July 5th. The shares were sold at an average price of $55.06, for a total transaction of $412,950.00. Following the sale, the director now owns 211,842 shares of the company’s stock, valued at $11,664,020.52. The disclosure for this sale can be found here. In the last three months, insiders sold 123,622 shares of company stock worth $6,241,605. 3.40% of the stock is owned by insiders.

Blueprint Medicines Corporation Company Profile

Blueprint Medicines Corporation is a biopharmaceutical company. The Company focuses on patients with genomically defined diseases driven by abnormal kinase activation. It focuses on crafting drug candidates that provide clinical responses to patients without adequate treatment options. It has developed a small molecule drug pipeline in cancer and a genetic disease.

Want to see what other hedge funds are holding BPMC? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Blueprint Medicines Corporation (NASDAQ:BPMC).

Institutional Ownership by Quarter for Blueprint Medicines Corporation (NASDAQ:BPMC)

Receive News & Ratings for Blueprint Medicines Corporation Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Blueprint Medicines Corporation and related companies with Analyst Ratings Network's FREE daily email newsletter.